Oncolytics Biotech Inc
ONCY0.994USD
-0.016-1.62%
Market hours （ET）Quotes delayed by 15 min
102.97MMarket Cap
LossP/E TTM
More Details of Oncolytics Biotech Inc Company
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Oncolytics Biotech Inc Info
Ticker SymbolONCY
Company nameOncolytics Biotech Inc
IPO dateOct 05, 2001
CEOKelly (Jared Ryan)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endOct 05
Address804, 322 - 11 Avenue Sw
CityCALGARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT2R 0C5
Phone14036707377
Websitehttps://www.oncolyticsbiotech.com/
Ticker SymbolONCY
IPO dateOct 05, 2001
CEOKelly (Jared Ryan)
Company Executives of Oncolytics Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
835.55K
+1.14%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
351.20K
+0.56%
Ms. Amy G. Levin
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
210.12K
+0.94%
Ms. Deborah M. Brown
Ms. Deborah M. Brown
Independent Director
Independent Director
84.85K
+46.09%
Mr. Jared Kelly
Mr. Jared Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
73.90K
+46.63%
Mr. Andrew Aromando
Mr. Andrew Aromando
Chief Business Officer
Chief Business Officer
25.50K
--
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Director
Independent Director
--
--
Dr. Thomas C. Heineman, Ph.D.
Dr. Thomas C. Heineman, Ph.D.
Chief Medical Officer of Oncolytics Biotech (U.S.)
Chief Medical Officer of Oncolytics Biotech (U.S.)
--
--
Ms. Angela Frances Holtham
Ms. Angela Frances Holtham
Independent Director
Independent Director
--
--
Mr. Jon Patton
Mr. Jon Patton
Director - Investor Relations and Communication
Director - Investor Relations and Communication
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kirk J. Look
Mr. Kirk J. Look
Chief Financial Officer
Chief Financial Officer
835.55K
+1.14%
Ms. Allison Hagerman
Ms. Allison Hagerman
Vice President - Product Development
Vice President - Product Development
351.20K
+0.56%
Ms. Amy G. Levin
Ms. Amy G. Levin
Vice President - Clinical Operations
Vice President - Clinical Operations
210.12K
+0.94%
Ms. Deborah M. Brown
Ms. Deborah M. Brown
Independent Director
Independent Director
84.85K
+46.09%
Mr. Jared Kelly
Mr. Jared Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
73.90K
+46.63%
Mr. Andrew Aromando
Mr. Andrew Aromando
Chief Business Officer
Chief Business Officer
25.50K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Look (Kirk J)
0.78%
Heineman (Thomas Ph.D.)
0.72%
Citadel Advisors LLC
0.35%
Seizinger (Bernd R.)
0.34%
Morgan Stanley & Co. LLC
0.34%
Other
97.47%
Shareholders
Shareholders
Proportion
Look (Kirk J)
0.78%
Heineman (Thomas Ph.D.)
0.72%
Citadel Advisors LLC
0.35%
Seizinger (Bernd R.)
0.34%
Morgan Stanley & Co. LLC
0.34%
Other
97.47%
Shareholder Types
Shareholders
Proportion
Individual Investor
3.27%
Investment Advisor
1.08%
Research Firm
0.65%
Hedge Fund
0.45%
Investment Advisor/Hedge Fund
0.38%
Bank and Trust
0.09%
Other
94.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
91
1.43M
1.47%
-4.31M
2025Q2
102
4.52M
5.33%
-5.05M
2025Q1
104
4.96M
5.73%
-3.99M
2024Q4
101
4.24M
5.41%
-4.27M
2024Q3
98
4.07M
5.31%
-2.47M
2024Q2
96
4.21M
5.50%
-2.38M
2024Q1
94
4.31M
5.68%
-2.07M
2023Q4
88
6.04M
8.31%
-1.35M
2023Q3
86
7.11M
9.98%
+4.75M
2023Q2
85
1.77M
2.73%
-692.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Look (Kirk J)
835.55K
0.94%
+9.40K
+1.14%
Aug 18, 2025
Heineman (Thomas Ph.D.)
776.00K
0.87%
+7.97K
+1.04%
Aug 18, 2025
Seizinger (Bernd R.)
366.99K
0.41%
+26.34K
+7.73%
Jul 16, 2025
Hagerman (Allison)
351.20K
0.4%
+1.97K
+0.56%
Aug 18, 2025
Pisano (Wayne)
258.31K
0.29%
+34.54K
+15.44%
Jul 16, 2025
Seeds Investor LLC
223.77K
0.25%
+33.83K
+17.81%
Jun 30, 2025
Levin (Amy G)
210.12K
0.24%
+1.97K
+0.94%
Aug 18, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Oncolytics Biotech Inc?
The top five shareholders of Oncolytics Biotech Inc are:
Look (Kirk J) holds 835.55K shares, accounting for 0.94% of the total shares.
Heineman (Thomas Ph.D.) holds 776.00K shares, accounting for 0.87% of the total shares.
Seizinger (Bernd R.) holds 366.99K shares, accounting for 0.41% of the total shares.
Hagerman (Allison) holds 351.20K shares, accounting for 0.40% of the total shares.
Pisano (Wayne) holds 258.31K shares, accounting for 0.29% of the total shares.
Look (Kirk J) holds 835.55K shares, accounting for 0.94% of the total shares.
Heineman (Thomas Ph.D.) holds 776.00K shares, accounting for 0.87% of the total shares.
Seizinger (Bernd R.) holds 366.99K shares, accounting for 0.41% of the total shares.
Hagerman (Allison) holds 351.20K shares, accounting for 0.40% of the total shares.
Pisano (Wayne) holds 258.31K shares, accounting for 0.29% of the total shares.
What are the top three shareholder types of Oncolytics Biotech Inc?
The top three shareholder types of Oncolytics Biotech Inc are:
Look (Kirk J)
Heineman (Thomas Ph.D.)
Citadel Advisors LLC
Look (Kirk J)
Heineman (Thomas Ph.D.)
Citadel Advisors LLC
How many institutions hold shares of Oncolytics Biotech Inc (ONCY)?
As of 2025Q3, 91 institutions hold shares of Oncolytics Biotech Inc, with a combined market value of approximately 1.43M, accounting for 1.47% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.86%.
What is the biggest source of revenue for Oncolytics Biotech Inc?
In --, the -- business generated the highest revenue for Oncolytics Biotech Inc, amounting to -- and accounting for --% of total revenue.
